Market Data graphic

Diversified Industries

You are here

This sector includes a wide-variety of issuers. Included in this group are companies involved in Financial Services, Real Estate, Media, Consumer and Industrial Products.

Diversified industries companies listed on CSE

Eat & Beyond Global Holdings Inc. is an investment issuer that identifies and makes equity investments in global plant based protein companies that are developing and commercializing innovative food tech as well as alternative food products. The company provides retail investors with the unique opportunity to participate in the growth of a broad cross-section of opportunities in the alternative food sector, and access companies that are leading the charge toward a smarter, more secure food supply.

Each Warrant shall entitle each Warrantholder thereof, upon exercise at any time after the Issue Date and prior to the Expiry Time, to acquire one (1) Warrant Share upon payment of the Exercise Price of $0.75.

See the Warrant Indenture for full details

Emergence Global Enterprises Inc. is a vertically integrated agribusiness company with a footprint in functional wellness products and brands. The “Emergence footprint" is a vertical integration of hydroponic research encompassing vertical farming, AI-focused orbital growing, aquaponics and greenhouse growing. At the centre of the "Emergence footprint" is a 20-acre "Centre for Agriculture and Farming Innovation", which will be the blueprint for supplying remote regions, drought-stricken regions and urban populations with steady food sources accessible and sustainable with limited impact on the environment.

 

EMERGIA operates mainly in Canada in the development, acquisition and management of multi-purpose real estate, including retail, multi-residential, industrial, and office buildings as well as land for future development. The Corporation’s investment platform is based on an integrated, agile and efficient develop-to-own strategy that enables EMERGIA to benefit from development profits and the value-add while securing stable long-term returns.

Fineqia provides a U.K. regulated platform and associated services to support and administer debt and equity security issuances such as corporate mini-bonds. The Company's strategy involves investments in and acquisitions of companies developing and propagating blockchain based financial solutions, adjunct to its core business of placing debt and equity securities. Fineqia brings an issuing company’s debt or equity offerings to the market by distributing and marketing securities for subscription by crowd investors such as accredited investors, high net worth individuals, family offices and fund managers. Fineqia does not provide investment advice and instead seeks to provide transparency by objectively outlining the potential risks and returns of various financing opportunities.

For more information, visit www.fineqia.com. 

.

The Company provides Advisory Services to companies and invests across a diversified portfolio of different asset classes, including equity and convertible note investments in large and small cap public listed and private companies. The Company also invests in technology companies involved in the development of blockchain solutions as well as direct investments in established and liquid Cryptocurrency (for example Bitcoin and Ethereum). 

The Exchange has determined that Gencan Capital Inc. (the “Issuer”) has not met the continued listing requirements as set out in CSE Policy 2, Appendix A section 2.9.

Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.

Trading remains halted pending a fundamental change as described in Policy 8.  The corporate actions announced in bulletin 2023-0211 does not represent Exchange approval, conditional or otherwise, of the fundamental change transaction.

The Exchange has determined that the Issuer has not met the continued listing requirements as set out in CSE Policy 2, Appendix A section 2.9.

Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.

Investor Note: In addition to the 4,733,706 Subordinate Voting Shares that are listed, there are 815.667 Multiple Voting Shares issued and outstanding but not listed.  The total number of equity shares assuming all of the Multiple Voting Shares are converted into the listed class would be 5,549,373.

Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies as well as medical marijuana pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant position in early stage investment opportunities that adequately reflect the risk profile.

Global Hemp Group Inc. (CSE: GHG / OTCQB: GBHPF / FRANKFURT: GHG) is focused on a executing a multi-phased strategy to become a leader in the industrial hemp industry. To further support and innovate, GHG has established a R&D Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D. whose career has focused in the areas of applied science and technology. The R&D team will initially focus on development of Environmentally Friendly Construction Materials, Nanofertilizers and Enhanced Extraction from Hemp.

GHG has expanded its scope of business into natural biologic therapeutics having acquired the exclusive North America licensing of patents and IP from Apollon Formularies plc, a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform. GHG will look to begin sub-licensing this IP throughout Canada, the United States and Mexico where legally permitted to do so.

Contact The Team

How can we help you?

Contact the CSE team to find out more.

Advertisement

Publicité

Latest CSE News

Advertisement

Publicité